Abbas Mansour, MD
Pulmonary Disease · Easley, SCNPI 1326092156
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $20,980 of the $31,843 with a category attached, or 65.9%. 41 manufacturers reported payments, led by GSK at 45.6% of the total. 2025 is the largest year on record at $14,370, 6.5 times the $2,222 reported in 2019. Among pulmonary disease clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,118 payments — averaging $28.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$15K
- AstraZeneca$5K
- Boehringer Ingelheim$2K
- Insmed, Inc.$1K
- Grifols USA, LLC$976
- Regeneron Healthcare Solutions, Inc.$946
- plus $7K from 35 others
Across 32 payments — averaging $5696.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$105K
- Sanofi US Services Inc.$42K
- AstraZeneca$31K
- Chiesi USA, Inc.$4K
What the payments were for
- Speaking & faculty fees$9,75031%
- Travel & lodging$7042%
- Food & beverage$20,98066%
- Education$3911%
- Gifts$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$31,843 in reported general payments places this provider in the 90th percentile of 192 pulmonary disease providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 912 | $748,450 |
| GlassiaAlpha-1-Proteinase Inhibitor | 39 | $374,013 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 481 | $352,079 |
| TezspireTezepelumab-Ekko | 72 | $313,652 |
| NucalaMepolizumab | 85 | $312,650 |
| Dupixent SyringeDupilumab | 65 | $293,518 |
| XolairOmalizumab | 97 | $251,542 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 12 | $200,639 |
| Fasenra PenBenralizumab | 36 | $198,357 |
| Dupixent PenDupilumab | 45 | $169,225 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 12 | $134,450 |
| EsbrietPirfenidone | 11 | $117,058 |
| ZemairaAlpha-1-Proteinase Inhibitor | 11 | $115,836 |
| Spiriva RespimatTiotropium Bromide | 77 | $53,181 |
| Breo ElliptaFluticasone/Vilanterol | 93 | $48,884 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $14,526 | $1,121,4991,114 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort, Airsupra | $5,444 | $716,534696 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Glassia | $729 | $374,01339 claims |
| Grifols USA, LLCProlastin C | $976 | $134,45012 claims |
| Genentech USA, Inc.Esbriet | $275 | $117,05811 claims |
| CSL BehringZemaira | $46 | $115,83611 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $2,029 | $81,460118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 192 pulmonary disease providers in South Carolina.
Other pulmonary disease in Easley
- Abhijit RavalAnderson$2M
- Richard BoganColumbia$1.1M
- Joseph BosciaSpartanburg$701K
- Patrick FlumeCharleston$418K
- Sean CallahanGreenville$321K
- Laura HerpelColumbia$254K
- Gerard SilvestriCharleston$254K
- Arun AdlakhaRock Hill$184K
- Jake KriegmdColumbia$112K
- Mark MaysonColumbia$86K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.